Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 1Atrial Fibrillation 1

Interventions

Oxaliplatin 9Fluorouracil 9pembrolizumab 7Paclitaxel 6Leucovorin 6Trastuzumab 5Capecitabine 5Specimen Handling 4Radiation 4Cisplatin 4Carboplatin 4tislelizumab 3patritumab deruxtecan 3Taxes 3Surgical Procedures, Operative 3Radiotherapy 3Nivolumab 3ulixertinib 2trastuzumab deruxtecan 2trastuzumab biosimilar HLX02 2durvalumab 2Ramucirumab 2Pemetrexed 2PF-05280014 2Ontruzant 2Ogivri 2Magnetic Resonance Spectroscopy 2Irinotecan 2Immunotherapy 2Exercise 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Amiodarone × 30 days × Clear all
NCT06067438 2026-05-22

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Atrial Fibrillation, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡